Abstract: An object of the present invention is to provide a process for conveniently and efficiently producing high purity thioredoxin from yeast. In the production of thioredoxin using yeast, thioredoxin is produced through the following steps (i) to (iii): (1) culturing the yeast; (2) stressing the yeast obtained in step (1) to cause a release of thioredoxin from a cell of the yeast; and (3) collecting the thioredoxin released from the yeast cell.

Abstract: Disclosed is a screening method which can select a substance having an influence on the binding between thioredoxin and MIF.

Abstract: [Problems] To provide a novel protease inhibitor and curative remedies and a therapeutic method for chronic obstructive pulmonary disease, immunodeficiency syndrome, alveolar proteinosis and circulatory diseases. [Means for Solving Problems] A protease inhibitor and a preventive or a remedy for chronic obstructive pulmonary disease or immunodeficiency syndrome characterized by containing at least one member selected from among redox active proteins and genes encoding the same and a preventive or a remedy for chronic obstructive pulmonary disease, alveolar proteinosis or circulatory diseases characterized by containing at least one member selected from IL-18 and a gene encoding the same.

Abstract: A novel pharmaceutical application of an extract from a vaccine virus-inoculated and inflamed tissue and relates to a thioredoxin production promoting agent containing the extract as an active ingredient. The extract has an excellent thioredoxin production promoting action against an oxidative stress caused by a stimulus by such as a tobacco smoke extract or hydrogen peroxide and showed a significant lung cell protective effect. Therefore, the pharmaceutical of the invention containing the extract as an active ingredient is highly useful as a preventive or therapeutic agent for a chronic obstructive lung disease considered to be mainly caused by a continuous oxidative stress such as chronic smoking and the pharmaceutical with less side effects and high safety.

Abstract: Disclosed is a screening method which can select a substance having an influence on the binding between thioredoxin and MIF.

Abstract: A novel pharmaceutical application of an extract from a vaccine virus-inoculated and inflamed tissue and relates to a thioredoxin production promoting agent containing the extract as an active ingredient. The extract has an excellent thioredoxin production promoting action against an oxidative stress caused by a stimulus by such as a tobacco smoke extract or hydrogen peroxide and showed a significant lung cell protective effect. Therefore, the pharmaceutical of the invention containing the extract as an active ingredient is highly useful as a preventive or therapeutic agent for a chronic obstructive lung disease considered to be mainly caused by a continuous oxidative stress such as chronic smoking and the pharmaceutical with less side effects and high safety.

Abstract: [Problems] The present invention aims to provide a preventive or therapeutic agent for inflammatory ocular-surface diseases. [Means for Solving Problems] The present invention provides a preventive or therapeutic agent for inflammatory ocular-surface diseases, which comprises polypeptides of thioredoxin superfamily as an active ingredient.

Abstract: An object of the present invention is to provide a process for conveniently and efficiently producing high purity thioredoxin from yeast. In the production of thioredoxin using yeast, thioredoxin is produced through the following steps (i) to (iii): (1) culturing the yeast; (2) stressing the yeast obtained in step (1) to cause a release of thioredoxin from a cell of the yeast; and (3) collecting the thioredoxin released from the yeast cell.

Abstract: (Problems) The main object of the present invention is to provide a screening method for selecting a substance affecting a bond between thioredoxin and MIF. (Means for Solving Problems) The present invention provides a screening method for selecting a test substance which strengthens a bond between a polypeptide of a thioredoxin family and a macrophage migration inhibition factor, comprising: mixing a test substance with at least one binding substance selected from following (1) to (4), (1) the polypeptide belonging to the thioredoxin family, (2) a protein having an amino acid sequence of the polypeptide belonging to the thioredoxin family in which one or more amino acid is deleted, replaced or added, and having an equivalent activity to the polypeptide of the thioredoxin family, (3) a gene coding (1), (4) a gene coding (2); bonding the binding substance to the macrophage migration inhibition factor; and monitoring the bond state between the binding substance and the macrophage migration inhibition factor.

Abstract: The present invention provides a preventive or therapeutic agent being effective for disorders induced by macrophage migration inhibitory factor and vascular system disorders, and having fewer side effects. In particular, the present agent is characterized by containing anti TRX antibody polypeptide as an active ingredient to inhibit adherence of leukocyte to vascular endothelial cell and a cell internalization of the macrophage migration inhibitory factor.

Abstract: The present invention relates to a human modified thioredoxin composed of any of the following polypeptides: (a) a polypeptide modified by alteration or chemical modification of a cysteine residue at position 35 with another amino acid in an amino acid sequence of SEQ ID NO:2; and (b) a polypeptide having an amino acid sequence having one or more substituted, deleted, inserted or added amino acids in positions except for positions 32 and 35, preferably positions 32 to 35 in the amino acid sequence of SEQ ID NO:2, and having an apoptosis-inducing activity.

Abstract: The object of the invention is to provide animal model of disorder and method of screening an agent for preventing or treating Metabolic Syndrome by using the animal model, wherein said animal model is used as experimental material which is essential to detailed analysis of component and pathologic condition of Metabolic Syndrome and to development of the method for treating and the agent for preventing and treating the Metabolic Syndrome. The above object is achieved by the non-human mammal model of disorders, whose TBP-2 gene is functionally deficient on chromosome, wherein the disorders are caused by impaired fatty acid utilization, and a method of screening an agent for preventing or treating Metabolic syndrome comprising; administering a test article to the non-human mammal whose TBP-2 gene is functionally deficient on chromosome.

Abstract: ABSTRACT The present invention relates to a human modified thioredoxin composed of any of the following polypeptides:(a) a polypeptide modified by alteration or chemical modification of a cysteine residue at position 35 with another amino acid in an amino acid sequence of SEQ ID NO:2; and (b) a polypeptide having an amino acid sequence having one or more substituted, deleted, inserted or added amino acids in positions except for positions 32 and 35, preferably positions 32 to 35 in the amino acid sequence of SEQ ID NO:2, and having an apoptosis-inducing activity.

Abstract: The object of the invention is to provide animal model of disorder and method of screening an agent for preventing or treating Metabolic Syndrome by using the animal model, wherein said animal model is used as experimental material which is essential to detailed analysis of component and pathologic condition of Metabolic Syndrome and to development of the method for treating and the agent for preventing and treating the Metabolic Syndrome. The above object is achieved by the non-human mammal model of disorders, whose TBP-2 gene is functionally deficient on chromosome, wherein the disorders are caused by impaired fatty acid utilization, and a method of screening an agent for preventing or treating Metabolic syndrome comprising; administering a test article to the non-human mammal whose TBP-2 gene is functionally deficient on chromosome.

Abstract: The present invention provides a therapeutic agent for treating inflammatory bowel diseases comprising as an active ingredient at least one member selected from polypeptides belonging a family exhibiting thioredoxin activity.

Abstract: Preventive or therapeutic agents for controlling various disorders induced by toxic substances in smoke produced by the combustion of fibers such as tobacco are disclosed. A polypeptide of the thioredoxin family (TRX) prevents toxic substances in smoke, produced by the combustion of fibers such as tobacco, from inducing inflammatory reactions and tissue fibrosis. Accordingly, TRX is effective for controlling of a wide range of disorders caused by toxic substances contained in smoke produced by combustion of fibers. The object of the present invention is to provide the preventive or therapeutic agents for disorders caused by toxic substances contained in smoke produced by combustion of fibers comprising an effective amount of polypeptide of thioredoxin family and/or one or more of its inducers.

Abstract: The present invention provides a therapeutic agent for treating inflammatory bowel diseases comprising as an active ingredient at least one member selected from polypeptides belonging a family exhibiting thioredoxin activity.

Abstract: The present invention relates to a therapeutic agent for treating acute hepatitis and chronic hepatitis (including hepatic fibrosis and hepatic cirrhosis) comprising as active ingredient one or more polypeptide or polypeptides selected from the polypeptides belonging to the family having thioredoxin activity.

Abstract: This invention discloses the isolation and purification of gene sequences which code upon expression a soluble form of the traditionally membrane bound immuno-regulatory protein, CD23. This protein regulates the amount of IgE present in the blood and upon cloning and amplification, procedures may be used in the treatment of IgE mediated diseases.

Abstract: A composition and method for the treatment of inflammation, rheumatism, autoimmune disease, ischemic damage of organs, drug toxicity and arteriosclerosis comprising human ADF is disclosed.